<DOC>
	<DOCNO>NCT00827762</DOCNO>
	<brief_summary>The purpose study determine whether improvement behavior occur child phenylketonuria ( PKU ) take Kuvan .</brief_summary>
	<brief_title>Behavioral Effects Kuvan Children With Mild Phenylketonuria</brief_title>
	<detailed_description>Little research conduct examine behavior cognition child mild PKU/hyperphenylalanemia , evidence reduction general intelligence ( IQ ) ( Costello , 1994 ) impairment executive ability ( Diamond , 1994 ; Gassio , 2005 ) population . It important note phenylalanine level child mild PKU approximately equivalent child classical PKU whose phenylalanine level manage dietary control . In child diet-treated PKU , impairments behavior cognition well-documented , particularly relation executive ability ( Christ , 2006 ; White , 2001 , 2002 ) . Taken together , finding suggest child mild PKU risk behavioral cognitive impairment , possible impairment may mitigate lower phenylalanine level treatment Kuvan . To investigate issue , approximately 20 child mild PKU 6 18 year age ( inclusive ) parent participate study . The behavior cognition child mild PKU assess use follow method : ( 1 ) Parents complete inventory rate behavior cognition child ; ( 2 ) Older child complete self-report inventory rate behavior cognition ; ( 3 ) Cognitive task assess IQ executive aspect attention ( i.e. , sustained attention inhibitory control ) administer child . The primary objective two-fold . First , determine behavior cognition compromise child mild PKU prior treatment Kuvan ( baseline ) . To accomplish objective , administer measure behavior cognition include normative data base age . We hypothesize child mild PKU rating score ≥ 1 standard deviation normative mean . Second , determine behavior cognition improve child mild PKU follow treatment Kuvan . To accomplish objective , administer measure behavior cognition 4 24 week treatment Kuvan ( 4-week 24-week follow-up , respectively ) . We hypothesize follow-up rating score child mild PKU improve ≥ 0.5 standard deviation relative baseline rating score .</detailed_description>
	<mesh_term>Phenylketonurias</mesh_term>
	<criteria>Willing able provide inform consent and/or assent . Willing able comply study procedure . Between 6 18 year age , inclusive . Intention physician prescribe Kuvan . Phenylalanine level 360μmol/L 600μmol/L , inclusive , untreated dietary restriction . Negative pregnancy test childbearing potential . Willing use contraception sexually active . Treatment Kuvan within past 6 month . Pregnant , breastfeeding , plan become pregnant study . Use investigational product le 30 day prior study . Concurrent condition could interfere participation safety . Any condition create high risk poor compliance study . History major medical disorder unrelated phenylketonuria . Perceived unreliable unavailable study . Use LDopa , methotrexate , drug inhibit folate metabolism . Known hypersensitivity sapropterin excipients .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>phenylketonuria</keyword>
	<keyword>Kuvan</keyword>
	<keyword>sapropterin</keyword>
	<keyword>behavior</keyword>
	<keyword>cognition</keyword>
	<keyword>executive ability</keyword>
	<keyword>attention</keyword>
</DOC>